Posted by Michael Wonder on 16 May 2017
Biohaven's trigriluzole receives fast track designation from U.S. FDA
15 May 2017 - Potential first-in-class therapy for spinocerebellar ataxia.
Biohaven Pharmaceutical announced today that the U.S. FDA has granted the company fast track designation for Biohaven’s product candidate trigriluzole (BHV-4157) for the potential treatment of Spinocerebellar Ataxia (SCA).
Trigriluzole previously received orphan drug designation from the FDA for the treatment of SCA in 2016. Biohaven is currently conducting a Phase 2/3 clinical trial in patients with SCA, with topline results expected in 2018.
